Background: Patients affected by poverty-related infectious diseases (PRDs) are disproportionally affected by malnutrition. To optimize treatment of patients affected by PRDs, we aimed to assess the influence of malnutrition associated with PRDs on drug pharmacokinetics, by way of a systematic review.
Methods: A systematic review was performed on the effects of malnourishment on the pharmacokinetics of drugs to treat PRDs, including HIV, tuberculosis, malaria, and neglected tropical diseases.
Results: In 21/29 PRD drugs included in this review, pharmacokinetics were affected by malnutrition. Effects were heterogeneous, but trends were observed for specific classes of drugs and different types and degrees of malnutrition. Bioavailability of lumefantrine, sulfadoxine, pyrimethamine, lopinavir, and efavirenz was decreased in severely malnourished patients, but increased for the P-glycoprotein substrates abacavir, saquinavir, nevirapine, and ivermectin. Distribution volume was decreased for the lipophilic drugs isoniazid, chloroquine, and nevirapine, and the α1-acid glycoprotein-bound drugs quinine, rifabutin, and saquinavir. Distribution volume was increased for the hydrophilic drug streptomycin and the albumin-bound drugs rifampicin, lopinavir, and efavirenz. Drug elimination was decreased for isoniazid, chloroquine, quinine, zidovudine, saquinavir, and streptomycin, but increased for the albumin-bound drugs quinine, chloroquine, rifampicin, lopinavir, efavirenz, and ethambutol. Clinically relevant effects were mainly observed in severely malnourished and kwashiorkor patients.
Conclusions: Malnutrition-related effects on pharmacokinetics potentially affect treatment response, particularly for severe malnutrition or kwashiorkor. However, pharmacokinetic knowledge is lacking for specific populations, especially patients with neglected tropical diseases and severe malnutrition. To optimize treatment in these neglected subpopulations, adequate pharmacokinetic studies are needed, including severely malnourished or kwashiorkor patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545752 | PMC |
| http://dx.doi.org/10.1007/s40262-021-01031-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicted environmental concentration (PEC), environmental risk assessment (ERA) and prioritization of antiretroviral drugs (ARVs) in seawater from Guarujá (Brazilian coastal zone).
Mar Environ Res
January 2025
Laboratório de Pesquisa em Produtos Naturais, Universidade Santa Cecília (UNISANTA), Rua Oswaldo Cruz, 266, C21, bloco C, Boqueirão, Santos, 11045-907, São Paulo, Brazil. Electronic address:
The antiretroviral therapy program's success in managing the human immunodeficiency virus (HIV) has inadvertently led to the release of antiretrovirals (ARVs) into worldwide aquatic ecosystems. However, few studies investigated the risks of ARV loadings that flow continuously to the marine waters of South America (such as Brazil). Against this backdrop, the aims of this study were: (i) to estimate the Predicted Environmental Concentration (PEC) of thirteen ARVs worldwide used in HIV treatment, and which are frequently disposed of in the marine aquatic ecosystems of Guarujá, São Paulo coastline, Brazil.
View Article and Find Full Text PDFPharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005.
Clin Pharmacokinet
December 2024
Sérgio Arouca National School of Public Health ENSP Fiocruz, Rio de Janeiro, RJ, Brazil.
Background And Objective: Advances in antiretroviral therapy led to an increase in life expectancy among people living with human immunodeficiency virus (HIV). As aging is characterized by several physiological changes that can influence pharmacokinetics (PK), this systematic review aims to describe the impact of aging on the PK of antiretrovirals (ARV) approved by the Food and Drug Administration (FDA) before 2005.
Methods: Searches were performed in BVS, EMBASE, and PubMed databases for publications until June 2024.
Adverse perinatal outcomes associated with different classes of antiretroviral drugs in pregnant women with HIV.
AIDS
February 2025
National Perinatal Epidemiology Unit, Infectious Disease Epidemiology Unit, Nuffield Department of Population Health.
Article Synopsis
- Women living with HIV (WLHIV) face higher risks of negative pregnancy outcomes compared to HIV-negative women, even when on antiretroviral therapy (ART).
- A systematic review and meta-analysis were conducted to evaluate the perinatal risks among WLHIV using different ART regimens (NNRTI, PI, and INSTI) versus HIV-negative women, analyzing 22 cohort studies involving over 191,000 women.
- Results showed that WLHIV on NNRTI-based ART had significantly increased risks for several adverse outcomes, such as preterm birth and low birthweight, highlighting the impact of ART types on pregnancy health.
Liver Injury in People With HIV on Antituberculosis and/or Antiretroviral Therapy-Assessing Causality Using the Updated Roussel Uclaf Causality Assessment Method.
Pharmacoepidemiol Drug Saf
October 2024
Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
Article Synopsis
- The study compared the Roussel Uclaf Causality Assessment Method (RUCAM) with a multidisciplinary expert panel to assess drug-induced liver injury (DILI) from antituberculosis and antiretroviral therapies.
- It involved 48 participants, all of whom were people with HIV, with many on multiple potentially harmful medications, which made it challenging to identify the exact cause of liver injury.
- The results showed that the RUCAM had low sensitivity (7%) but high specificity (100%) in identifying probable or certain drug causes of liver injury, indicating it isn't very reliable in this context compared to the expert panel.
Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study.
Biomedicines
September 2024
Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé P.O. Box 1364, Cameroon.
Article Synopsis
- Mortality in children accounts for 15% of global AIDS-related deaths, with Cameroon facing a higher rate of 25%, mainly due to poor viral response.
- A study analyzed viral suppression (VS) among Cameroonian children and young adults receiving antiretroviral therapy (ART) to identify factors affecting VS, finding an overall rate of 82.3%.
- Key findings revealed that younger age, longer ART duration, and certain non-DTG-based regimens were independent predictors of non-VS, suggesting the need for prioritizing transition to DTG-based regimens to improve outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!